Edition:
United States

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

4.41USD
15 Jun 2018
Change (% chg)

$0.47 (+11.93%)
Prev Close
$3.94
Open
$3.90
Day's High
$4.41
Day's Low
$3.90
Volume
31,086
Avg. Vol
13,438
52-wk High
$5.10
52-wk Low
$2.72

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 3.01
Market Cap(Mil.): $37.31
Shares Outstanding(Mil.): 8.46
Dividend: --
Yield (%): --

Financials

  TNXP.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -3.01 -- --
ROI: -113.22 -5.87 13.17
ROE: -113.31 -7.71 15.15

BRIEF-Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And Co

* TONIX PHARMACEUTICALS HOLDING CORP SAYS ON MAY 1, CO ENTERED INTO SALES AGREEMENT WITH COWEN AND CO RELATING TO SHARES OF CO'S COMMON STOCK OFFERED

May 17 2018

BRIEF-Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per Share

* TONIX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

May 14 2018

BRIEF-Tonix Pharmaceuticals Holding Qtrly Net Loss Per Common Share $0.88

* TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88 Source text: (https://bit.ly/2G8HkXY) Further company coverage:

May 11 2018

BRIEF-Tonix Pharmaceuticals Holding Says Files For Mixed Shelf Of Up To $75 Mln

* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:

May 01 2018

BRIEF-Tonix Pharmaceuticals Receives IND Clearance By U.S. FDA For TNX-102 SL

* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Tonix Pharmaceuticals To Present FDA Breakthrough Therapy Designated PTSD Program At Microcap Conference

* DESIGNATED PTSD PROGRAM AT THE MICROCAP CONFERENCE IN NEW YORK

Apr 04 2018

BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD

Apr 03 2018

BRIEF-Tonix Pharma Reports Q4 Loss Per Share $0.71

* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

Mar 12 2018

BRIEF-Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing

* BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2HcDj6B) Further company coverage:

Feb 13 2018

BRIEF-Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya

* TONIX PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT FOR THE ACTIVE INGREDIENT IN TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) Source text for Eikon: Further company coverage:

Jan 23 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.61 +0.20
Pfizer Inc. (PFE.N) $36.36 +0.20
Novartis AG (NOVN.S) CHF75.60 +0.10
AstraZeneca plc (AZN.L) 5,398.00 --
GlaxoSmithKline plc (GSK.L) 1,556.00 --

Earnings vs. Estimates